These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma. Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887 [TBL] [Abstract][Full Text] [Related]
6. Melanoma genetics: an update on risk-associated genes. Udayakumar D; Tsao H Hematol Oncol Clin North Am; 2009 Jun; 23(3):415-29, vii. PubMed ID: 19464594 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous melanoma susceptibility and progression genes. de Snoo FA; Hayward NK Cancer Lett; 2005 Dec; 230(2):153-86. PubMed ID: 16297704 [TBL] [Abstract][Full Text] [Related]
9. The role of B-RAF in melanoma. Gray-Schopfer VC; da Rocha Dias S; Marais R Cancer Metastasis Rev; 2005 Jan; 24(1):165-83. PubMed ID: 15785879 [TBL] [Abstract][Full Text] [Related]
10. Ras, Raf, and MAP kinase in melanoma. Solus JF; Kraft S Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084 [TBL] [Abstract][Full Text] [Related]
11. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. Hacker E; Hayward NK; Dumenil T; James MR; Whiteman DC J Invest Dermatol; 2010 Jan; 130(1):241-8. PubMed ID: 19571821 [TBL] [Abstract][Full Text] [Related]
12. Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis. Martins I; Sylla K; Deshayes F; Lauriol J; Ghislin S; Dieu-Nosjean MC; Viguier M; Verola O; Charron D; Alcaide-Loridan C; Al-Daccak R Melanoma Res; 2009 Aug; 19(4):226-37. PubMed ID: 19574933 [TBL] [Abstract][Full Text] [Related]
13. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. Hacker E; Nagore E; Cerroni L; Woods SL; Hayward NK; Chapman B; Montgomery GW; Soyer HP; Whiteman DC J Invest Dermatol; 2013 Apr; 133(4):1027-33. PubMed ID: 23096702 [TBL] [Abstract][Full Text] [Related]
15. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566 [No Abstract] [Full Text] [Related]
16. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. Council ML; Gardner JM; Helms C; Liu Y; Cornelius LA; Bowcock AM Exp Dermatol; 2009 May; 18(5):485-7. PubMed ID: 19320745 [TBL] [Abstract][Full Text] [Related]
17. Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects. Blokx WA; van Dijk MC; Ruiter DJ Histopathology; 2010 Jan; 56(1):121-32. PubMed ID: 20055910 [TBL] [Abstract][Full Text] [Related]
18. The molecular basis of melanomagenesis and the metastatic phenotype. Crowson AN; Magro C; Miller A; Mihm MC Semin Oncol; 2007 Dec; 34(6):476-90. PubMed ID: 18083371 [TBL] [Abstract][Full Text] [Related]
19. Molecular and genetic mechanisms in melanoma. Gruber F; Kastelan M; Brajac I; Saftić M; Peharda V; Cabrijan L; Stanić Zgombić Z; Simonić E Coll Antropol; 2008 Oct; 32 Suppl 2():147-52. PubMed ID: 19138018 [TBL] [Abstract][Full Text] [Related]
20. [New therapies targeting the genetic mutations responsible for different types of melanoma]. Botella-Estrada R; Sanmartín Jiménez O Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]